Amgen Positions Ivabradine As A Foot In The Door Ahead Of PCSK9 Launch

Amgen executives laid out the case for the heart failure candidate ivabradine, which will serve as a foundation for the launch of the company’s highly anticipated PCSK9 inhibitor, during a presentation at AHA. The company also presented the first 52-week data on evolocumab.